1711 results about "Colitis" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application of the bifidobacterium animalis subsp. Lactis, and belongs to the field of microorganisms. According to the invention, a strain of bifidobacterium anaticum subsp. Lactis LIHUO 01 is screened out, the strain is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number is GDMCC No: 65512. The invention also discloses a preparation method of the bifidobacterium anaticum subsp. Lactis strain, and the bifidobacterium anaticum subsp. Lactis strain has the advantages that the bifidobacterium anaticum subsp. Lactis strain can be used for preparing the bifidobacterium anaticum subsp. Lactis strain; the bifidobacterium animalis subsp. Lactis LIHUO 01 has good in-vitro probiotic characteristics, has the effects of relieving ulcerative colitis, improving constipation and regulating intestinal flora, and has a good application prospect in preparation of food or health care products or medicines for relieving ulcerative colitis or improving constipation or regulating intestinal flora.

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

An estimation system automatically estimates a severity of ulcerative colitis (UC) based on an endoscopic video. During a training phase, a training system trains one or more machine-learned models based on a set of training videos each annotated with a single video-level UC severity score representing an aggregate UC severity observed in the whole video. The one or more machine-learned models are capable of estimating UC severity depicted in an individual endoscopic video frame. Applying the one or more machine-learned models to an endoscopic test video of unknown UC severity enables estimation of frame-level UC severity scores for each frame of the test video. The frame-level UC severity scores may be represented on a continuous severity scale or may be mapped to discrete values on a predefined baseline severity scale such as a Mayo Endoscopic Subscore (MES) scale.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention discloses bifidobacterium animalis subsp. Lactis BLa79 as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC (China General Microbiological Culture Collection Center) NO. 32426, and the preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC NO. 32426. Based on the strain, the invention also provides application and related products of the strain. The BLa79 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora, can effectively relieve ulcerative colitis, and can relieve colitis by increasing body weight, reducing DAI score, reducing spleen index, inhibiting colonic atrophy, reducing proinflammatory factor level and promoting SIgA secretion.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The present invention relates to Obefazimod or a pharmaceutically acceptable salt thereof for use in the treatment of ulcerative colitis.

The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention relates to the technical field of functional microorganism screening and application, and particularly provides a strain of lactobacillus plantarum and an application of the lactobacillus plantarum in improvement of intestinal inflammation and repair of intestinal mucosa injury. The plant lactobacillus is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) on August 1, 2024, the address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the plant lactobacillus is CGMCC No.31521. The strain has remarkable antioxidant, bacteriostatic and anti-inflammatory effects, can repair intestinal barrier injury of mice with colitis, promote renewal of intestinal stem cells, promote growth of intestinal beneficial bacteria and inhibit proliferation of harmful bacteria, can be widely applied to prevention and treatment of enteritis, and has a wide market prospect.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention discloses application of polygonatum kingianum polysaccharide in preparation of medicine for treating ulcerative colitis, and relates to the field of biomedicine.The preparation method of the polygonatum kingianum polysaccharide comprises the following steps that S1, polygonatum kingianum roots are taken, smashed and then screened, and polygonatum kingianum powder is prepared; s2, the polygonatum kingianum powder obtained in the step S1 is soaked in an ethanol solution, and polygonatum kingianum powder residues are obtained; s3, performing water extraction on the polygonatum kingianum powder residues obtained in the step S2 to obtain an extracting solution; s4, concentrating the extracting solution obtained in the step S3, adding ethanol into the concentrated solution to precipitate polysaccharide, and centrifugally separating to obtain crude polysaccharide; the polygonatum kingianum polysaccharide disclosed by the invention is high in purity, the effectiveness of the polygonatum kingianum polysaccharide in treatment of ulcerative colitis is verified, and a new solution is provided for relieving the problem of shortage of current colitis treatment medicines.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention provides a drug-loaded callicarpa nudiflora-derived extracellular vesicle as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The drug-loaded callicarpa nudiflora-derived extracellular vesicle has relatively high encapsulation efficiency and drug loading rate and good gastrointestinal tract stability and biocompatibility, can target a colitis disease part to reduce adverse reaction of a drug and improve the curative effect, solves the problem that the drug is insoluble in water, and can be used for preparing the drug-loaded callicarpa nudiflora-derived extracellular vesicle. The invention provides a novel drug delivery strategy for treating the ulcerative colitis, and is expected to become an effective strategy for clinically treating the ulcerative colitis, thereby achieving the effects of synergistically treating the ulcerative colitis and improving the effectiveness and safety of drug delivery.

The invention discloses lactococcus lactis subsp. Lactis and application thereof in fermentation of American cockroach powder. The strain is separated and screened from the intestinal contents of the Amolops nobilis, grows well on an MRS agar culture medium, is not hemolyzed, is sensitive to various common antibiotics, has relatively strong adaptive capacity to the intestinal environment of human and animals, has relatively strong lactic acid production capacity, and has strong inhibition capacity to common intestinal pathogens of human and animals. When the strain is used for fermenting American cockroach powder, the content of bioactive substances such as amino acids, peptides, indoles, pyrimidine and purines can be greatly increased, fermented sterile supernate has an obvious effect on mouse colitis induced by DSS, and the inflammatory factor level is remarkably reduced; the strain opens up a new way for further development and utilization of the traditional Chinese medicinal material periplaneta americana.

The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.

The invention provides methods and compositions related to methods for determining whether a human subject having ulcerative colitis will respond to treatment with a humanized antibody having binding specificity for human α4β7 integrin for treating ulcerative colitis. The invention provides response markers that can be used to identify responders of ulcerative colitis.

The invention discloses a carrier-free nano-particle with pH / ROS dual response as well as a preparation method and application of the carrier-free nano-particle. The preparation method comprises the following steps: enabling quinolizidine alkaloid and flavonol to be subjected to self-assembly, so as to prepare quinolizidine alkaloid-flavonol carrier-free nano particles; modifying the quinolizidine alkaloid-flavonol carrier-free nano particles by adopting a phenylboronic acid-hyaluronic acid conjugate, so as to prepare nano particles modified by the phenylboronic acid-hyaluronic acid conjugate; and coating the surfaces of the nano-particles modified by the phenylboronic acid-hyaluronic acid conjugate with a pH sensitive polymer to prepare the pH / ROS dual-response carrier-free nano-particles. The sophocarpidine-kaempferol carrier-free nanoparticles with pH / ROS dual response, prepared by the invention, have the advantages of good targeting property, high biocompatibility, small toxicity and adverse reaction and the like, meanwhile, the nanoparticles have a good anti-inflammatory effect, and a new choice is provided for the treatment of ulcerative colitis.

The invention relates to the technical field of biological medicines, and particularly discloses application of gambogic acid in preparation of a medicine for treating ulcerative colitis. The gambogic acid provided by the invention can be used for preparing a programmed necrosis inhibitor and a medicine for treating ulcerative colitis, and the gambogic acid is beneficial to improving cell morphology, increasing cell viability and improving symptoms of ulcerative colitis caused by DSS. Chemical structure of gambogic acid: # imgabs0 #

The invention discloses lactobacillus reuteri with antioxidant, anti-inflammatory and anti-hypoxia capabilities, the name of the lactobacillus reuteri is QM11, the classification name of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation date of the lactobacillus reuteri is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on August 5, 2024, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541. The preservation unit is China General Microbiological Culture Collection Center (CGMCC). The lactobacillus reuteri is separated from faeces of healthy yaks in Qinghai province, has relatively strong acid and cholate tolerance, has relatively good antioxidant and anti-inflammatory capacities, and has a relatively strong inhibition effect on pathogenic bacteria such as yak-derived pathogenic escherichia coli, staphylococcus aureus and salmonella typhimurium; the sodium dextran sulfate induced mouse colitis symptom is relieved, and the hypoxia tolerance of the mouse is improved. The lactobacillus reuteri disclosed by the invention can be used for preparing medicines or microecological preparations for resisting oxidation, inflammation and hypoxia, and has a very wide application prospect.

The invention relates to the technical field of microbial medicines, and particularly discloses Brawler's bacteria EMF75-02B1B and an application of the Brawler's bacteria EMF75-02B1B. The invention discloses Blauria sp. EMF75-02B1B, which is preserved in the Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Blauria sp. EMF75-02B1B is GDMCC No: 65084. A mouse model proves that the Brawler bacteria EMF75-02B1B can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight loss and colon shortening degree of the ulcerative colitis mouse, enhance the intestinal barrier function and relieve inflammatory response.

The invention belongs to the field of spaceflight purple corn RS3 type resistant starch, and particularly relates to spaceflight purple corn RS3 type resistant starch as well as a preparation method and application thereof. The preparation method comprises the following steps: adding water into spaceflight purple corn for blending to obtain starch milk; performing ultrasonic treatment on the starch milk, adjusting the starch milk to be acidic, and gelatinizing to obtain gelatinized starch; pullulanase is added into the gelatinized starch for enzymolysis, high-temperature enzyme deactivation is performed after enzymolysis is completed, then cooling, aging recovery, suction filtration and water washing are performed in sequence, and filter residues are obtained; and drying, crushing and sieving the filter residues. The invention provides a preparation method of spaceflight purple corn RS3 resistant starch, the problem that the prepared RS3 resistant starch is low in content and unstable is solved, and experiments prove that the spaceflight purple corn RS3 resistant starch can reduce the expression of inflammatory factors IL-6 and TNF-alpha in serum, and can reduce the content of the inflammatory factors IL-6 and TNF-alpha by adjusting the proportion of each flora in intestinal flora. Therefore, the steady state of the environment in the intestinal tract is controlled, and the effect of treating ulcerative colitis is achieved.

The present invention provides an application of a thorn sugar neutral polysaccharide in preparing a drug for preventing and / or treating ulcerative colitis, and belongs to the field of medical technology. Animal experimental results show that after the thorn sugar neutral polysaccharide is used in a mouse model of ulcerative colitis, the phenomenon of colon shortening can be alleviated, the production of harmful bacteria can be inhibited, the abundance of Helicobacter genus can be reduced, the number of beneficial bacteria can be increased, and the abundance of Lactobacillus genus, Bacteroides genus and Oscillatory Spirochete genus can be increased. Therefore, the thorn sugar neutral polysaccharide of the present invention can be used as a drug for preparing a drug for preventing or treating ulcerative colitis.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The present invention relates to the technical field of probiotics, and in particular to a strain of Lactobacillus casei ZKLc1221, its lactobacillus and its application in improving ulcerative colitis. Lactobacillus casei )ZKLc1221 has been deposited in the General Microbiology Center of China Microorganism Culture Collection Committee on June 21, 2023, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 27673. The lactobacillus obtained by optimizing the fermentation conditions of Lactobacillus casei ZKLc1221 provided by the present invention has good thermal stability, good effect in improving ulcerative colitis, and can significantly improve pathological damage to the colon.

The invention discloses an application of a Piezo1 inhibitor in preparation of a medicine for treating necrotizing enterocolitis. The Piezo1 inhibitor can be applied in preparation of the medicine for treating the necrotizing enterocolitis. The Piezo1 inhibitor can also be applied to preparation of drugs for relieving NEC intestinal epithelial barrier injury. The Piezo1 inhibitor can also be applied to preparation of drugs for reducing calcium influx in intestinal epithelial cells and calcium / calmodulin dependent protein kinase activity. The application has the beneficial effects that the effect and mechanism of the Piezo1 for regulating and controlling the calcium ion influx and promoting the NEC severity degree by the calcium / calmodulin dependent protein kinase activity level are discussed for the first time from multiple aspects of animals, tissues, cells, molecules and the like, and the effect and mechanism of the activated intestinal epithelial cell Piezo1 in NEC inflammatory injury and barrier repair are clarified for the first time; the knockout of the gene can improve the NEC severity of mice, and a new intervention target is provided for clinical treatment.